Dr. Pant on the Third-Line Setting for Metastatic CRC
Shubham Pant, MD
Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the third-line setting for patients with metastatic colorectal cancer (CRC).
According to Pant, there are not many options for patients with CRC in the third-line setting. Currently, regorafenib (Stivarga) and TAS-102 are the only options for this setting.
Next-generation sequencing is important to determine targets for treatment, explains Pant.